Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Morris

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Nature Communications|October 13, 2019
High-potency ligands for DREADD imaging and activation in rodents and monkeysJordi Bonaventura, Mark A G Eldridge, Feng Hu, et al.
Microorganisms|April 3, 2021
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In VivoCourtney L Finch, Julie Dyall, Shuang Xu, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Science Translational Medicine|November 22, 2019
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screeningGrant L Lin, Kelli M Wilson, Michele Ceribelli, et al.
Clinical Pharmacology and Therapeutics|July 26, 2024
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy VolunteersShruti M Raja, Jeffrey T Guptill, Michelle Mack, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Nature Communications|October 13, 2019
High-potency ligands for DREADD imaging and activation in rodents and monkeysJordi Bonaventura, Mark A G Eldridge, Feng Hu, et al.
Microorganisms|April 3, 2021
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In VivoCourtney L Finch, Julie Dyall, Shuang Xu, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Science Translational Medicine|November 22, 2019
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screeningGrant L Lin, Kelli M Wilson, Michele Ceribelli, et al.
Clinical Pharmacology and Therapeutics|July 26, 2024
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy VolunteersShruti M Raja, Jeffrey T Guptill, Michelle Mack, et al.
Pageof 5